FIELD: oral compositions.
SUBSTANCE: present invention relates to sustained release oral compositions of tofacitinib and its pharmaceutically acceptable salts.
EFFECT: compositions described herein have the desired pharmacokinetic characteristics.
25 cl, 49 tab, 18 ex
Title | Year | Author | Number |
---|---|---|---|
TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
METHODS AND MEDICINAL FORMULATIONS FOR CONTROLLED DELIVERY OF PALIPERIDONE | 2003 |
|
RU2321391C2 |
DOSAGE FORMS WITH RETARDED RELEASE OF ZIPRASIDONE | 2004 |
|
RU2351316C2 |
METHODS OF TREATING GASTROINTESTINAL TRACT DISORDERS INDEPENDENTLY ON FOOD CONSUMPTION | 2014 |
|
RU2563993C1 |
PHARMACEUTICAL COMPOSITION OF METFORMIN WITH PROLONGED RELEASE AND METHOD OF ITS OBTAINING | 2006 |
|
RU2433821C2 |
FORM OF PROLONGED VENLAFAXINE HYDROCHLORIDE LIBERATION | 2004 |
|
RU2340331C2 |
CONTROLLED-RELEASE HYDROCODON COMPOSITION | 2001 |
|
RU2253452C2 |
TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
ORAL VILDAGLIPTIN OSMOTIC PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2706706C1 |
Authors
Dates
2023-02-14—Published
2014-03-12—Filed